A reminder that stellar Australian researchers at the Murdoch Children's Research Centre pioneered this immune-system research & new recommendations on feeding babies & toddlers to avoid allergies where possible, now being confirmed worldwide. Yay. #MCRC #allergies
Feeding peanut products to infants was connected with a 43 percent lower association with developing peanut allergies, according to a recent study.
Here’s when experts recommend your kids try peanuts:
Here’s when experts recommend your kids try peanuts:
A big study links feeding babies peanuts to lower allergy risk. When to do it.
Experts recommend introducing peanuts to infants to prevent allergies, with a new study showing a 43 percent lower association with developing peanut allergies.
www.washingtonpost.com
October 28, 2025 at 10:06 AM
A reminder that stellar Australian researchers at the Murdoch Children's Research Centre pioneered this immune-system research & new recommendations on feeding babies & toddlers to avoid allergies where possible, now being confirmed worldwide. Yay. #MCRC #allergies
We were proud to see #TeamManchester present at over 10 sessions & 20+ posters at #ESMO2025.
Well done to everyone involved in representing the MCRC on this international stage & demonstrating the commitment of our researchers & clinicians!🐝
See you all in Spain for #ESMO26! 🇪🇸
Well done to everyone involved in representing the MCRC on this international stage & demonstrating the commitment of our researchers & clinicians!🐝
See you all in Spain for #ESMO26! 🇪🇸
October 24, 2025 at 9:38 AM
We were proud to see #TeamManchester present at over 10 sessions & 20+ posters at #ESMO2025.
Well done to everyone involved in representing the MCRC on this international stage & demonstrating the commitment of our researchers & clinicians!🐝
See you all in Spain for #ESMO26! 🇪🇸
Well done to everyone involved in representing the MCRC on this international stage & demonstrating the commitment of our researchers & clinicians!🐝
See you all in Spain for #ESMO26! 🇪🇸
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC
https://www.newsbeep.com/il/87371/
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over…
https://www.newsbeep.com/il/87371/
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over…
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC - Israel News Beep
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over
www.newsbeep.com
October 20, 2025 at 8:30 PM
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC
https://www.newsbeep.com/il/87371/
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over…
https://www.newsbeep.com/il/87371/
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over…
Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @oncodaily.bsky.social
October 20, 2025 at 7:11 AM
Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @oncodaily.bsky.social
If anyone wants to know a bit more about the history of "Excited Delirium" and how it came to be used, Behind the Bastards did a great 2 parter on it.
Heres Part 1:
www.youtube.com/watch?v=MCRc...
Heres Part 1:
www.youtube.com/watch?v=MCRc...
Part One: Excited Delirium: How Cops Invented A Disease | BEHIND THE BASTARDS
YouTube video by Behind the Bastards
www.youtube.com
October 9, 2025 at 2:42 PM
If anyone wants to know a bit more about the history of "Excited Delirium" and how it came to be used, Behind the Bastards did a great 2 parter on it.
Heres Part 1:
www.youtube.com/watch?v=MCRc...
Heres Part 1:
www.youtube.com/watch?v=MCRc...
First event of Mornington Chasers's winter Series Regent's Park 10k. After yesterday's Royal Park closed due to high winds, this morning it was crisp and clear sunshine with only a light breeze. I was the 70 mins pacer this run helped a few runners to get under that time. #running #10k #mcrc
October 5, 2025 at 3:49 PM
#DidYouKnow that each tumour has its own biology & biomarkers can help to reveal its specific characteristics?
On #WorldmCRCDay, people living with mCRC share how biomarker testing changed their care journey.
Learn more➡️ digestivecancers.eu/biomarkers-i...
#KnowYourBiomarkers
@fightcrc.bsky.social
On #WorldmCRCDay, people living with mCRC share how biomarker testing changed their care journey.
Learn more➡️ digestivecancers.eu/biomarkers-i...
#KnowYourBiomarkers
@fightcrc.bsky.social
September 24, 2025 at 9:13 AM
#DidYouKnow that each tumour has its own biology & biomarkers can help to reveal its specific characteristics?
On #WorldmCRCDay, people living with mCRC share how biomarker testing changed their care journey.
Learn more➡️ digestivecancers.eu/biomarkers-i...
#KnowYourBiomarkers
@fightcrc.bsky.social
On #WorldmCRCDay, people living with mCRC share how biomarker testing changed their care journey.
Learn more➡️ digestivecancers.eu/biomarkers-i...
#KnowYourBiomarkers
@fightcrc.bsky.social
#GI25 abstracts are out!
Almost 1000 abstracts and presentations!
Some highlights
CAR T For Solid Tumor (CRC)
GCC19 CART for refractory mCRC with a response rate of 80% at dose level 2! Some responses included complete metabolic response on PET (jaw dropping).
meetings.asco.org/abstracts-pr...
Almost 1000 abstracts and presentations!
Some highlights
CAR T For Solid Tumor (CRC)
GCC19 CART for refractory mCRC with a response rate of 80% at dose level 2! Some responses included complete metabolic response on PET (jaw dropping).
meetings.asco.org/abstracts-pr...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
January 22, 2025 at 1:35 AM
#GI25 abstracts are out!
Almost 1000 abstracts and presentations!
Some highlights
CAR T For Solid Tumor (CRC)
GCC19 CART for refractory mCRC with a response rate of 80% at dose level 2! Some responses included complete metabolic response on PET (jaw dropping).
meetings.asco.org/abstracts-pr...
Almost 1000 abstracts and presentations!
Some highlights
CAR T For Solid Tumor (CRC)
GCC19 CART for refractory mCRC with a response rate of 80% at dose level 2! Some responses included complete metabolic response on PET (jaw dropping).
meetings.asco.org/abstracts-pr...
The event was also held at a an aerospace company in Chandler, Advanced Materials Technologies, LLC which is owned by Daryl Jay Donkersloot. Donkersloot and his wife, Gayla Donkersloot, were some of the top funders of the Kari Lake U.S. Senate campaign and Daryl has donated nearly 70K to MCRC.
A reader asked where the money for the Senate race is coming from. We found out. And it's not Arizona.
Arizona is at the top of a list of states that will determine control of the U.S. Senate.
www.12news.com
March 25, 2025 at 8:08 PM
The event was also held at a an aerospace company in Chandler, Advanced Materials Technologies, LLC which is owned by Daryl Jay Donkersloot. Donkersloot and his wife, Gayla Donkersloot, were some of the top funders of the Kari Lake U.S. Senate campaign and Daryl has donated nearly 70K to MCRC.
Dual-targeted Therapy Plus Chemotherapy Doubles Survival in BRAF-Mutated Metastatic Colorectal Cancer
In a groundbreaking advancement that could redefine the prognosis for a challenging subset of metastatic colorectal cancer (mCRC) patients, the BREAKWATER phase 3 clinical trial has revealed…
In a groundbreaking advancement that could redefine the prognosis for a challenging subset of metastatic colorectal cancer (mCRC) patients, the BREAKWATER phase 3 clinical trial has revealed…
Dual-targeted Therapy Plus Chemotherapy Doubles Survival in BRAF-Mutated Metastatic Colorectal Cancer
In a groundbreaking advancement that could redefine the prognosis for a challenging subset of metastatic colorectal cancer (mCRC) patients, the BREAKWATER phase 3 clinical trial has revealed striking improvements in survival outcomes for individuals harboring the BRAF V600E mutation. This particular mutation, found in approximately 8 to 12 percent of colorectal cancer cases, has historically been associated with aggressive disease progression and poor response to conventional therapies.
scienmag.com
May 30, 2025 at 6:36 PM
Dual-targeted Therapy Plus Chemotherapy Doubles Survival in BRAF-Mutated Metastatic Colorectal Cancer
In a groundbreaking advancement that could redefine the prognosis for a challenging subset of metastatic colorectal cancer (mCRC) patients, the BREAKWATER phase 3 clinical trial has revealed…
In a groundbreaking advancement that could redefine the prognosis for a challenging subset of metastatic colorectal cancer (mCRC) patients, the BREAKWATER phase 3 clinical trial has revealed…
Abstract 3512: TRIPLETE (bit.ly/4kiMGnt). First-line treatment with modified FOLFOXIRI plus panitumumab improved OS over standard FOLFOX plus panitumumab in patients with unresectable, RAS/BRAF wild-type mCRC. #ASCO25 #gicsm
Program Guide – ASCO Meeting Program Guide
bit.ly
May 29, 2025 at 1:40 PM
Abstract 3512: TRIPLETE (bit.ly/4kiMGnt). First-line treatment with modified FOLFOXIRI plus panitumumab improved OS over standard FOLFOX plus panitumumab in patients with unresectable, RAS/BRAF wild-type mCRC. #ASCO25 #gicsm
Take your #mCRC care to the next level! Join us Aug. 20 📅 at 7:00 pm CT for Precision in Practice, a FREE webinar. Learn how early testing & collaboration can improve mCRC outcomes. Sponsored by an independent educational grant from Pfizer. Sign up here: www.asge.org/home/educati... #GISky #MedSky
July 31, 2025 at 1:22 PM
Take your #mCRC care to the next level! Join us Aug. 20 📅 at 7:00 pm CT for Precision in Practice, a FREE webinar. Learn how early testing & collaboration can improve mCRC outcomes. Sponsored by an independent educational grant from Pfizer. Sign up here: www.asge.org/home/educati... #GISky #MedSky
Join MCRC for Bridging the Gap: Housing Solutions at the Intersection of Reentry & Homelessness. Impact Justice, will give an overview of their model that directly connects people returning home from prison with residents who have space to share. buff.ly/ga1nAOZ
July 19, 2025 at 3:45 PM
Join MCRC for Bridging the Gap: Housing Solutions at the Intersection of Reentry & Homelessness. Impact Justice, will give an overview of their model that directly connects people returning home from prison with residents who have space to share. buff.ly/ga1nAOZ
This Black History Month, we celebrate Black leaders at the MCRC, highlighting their proudest moments, lessons learned, and hopes for the future.
www.mcrc.manchester.ac.uk/faces-of-lea...
www.mcrc.manchester.ac.uk/faces-of-lea...
Faces of Leadership: Black Scientists Shaping Cancer Research and Care - Manchester Cancer Research Centre
This Black History Month, we celebrate Black leaders at the Manchester Cancer Research Centre, highlighting their proudest moments, lessons learned, and hopes for the future.
www.mcrc.manchester.ac.uk
October 10, 2025 at 10:11 AM
This Black History Month, we celebrate Black leaders at the MCRC, highlighting their proudest moments, lessons learned, and hopes for the future.
www.mcrc.manchester.ac.uk/faces-of-lea...
www.mcrc.manchester.ac.uk/faces-of-lea...
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
#ColorectalCancer #CRCSM #ASCO25
@ascocancer.bsky.social www.onclive.com/view/nivolum...
#ColorectalCancer #CRCSM #ASCO25
@ascocancer.bsky.social www.onclive.com/view/nivolum...
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
May 31, 2025 at 3:35 PM
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
#ColorectalCancer #CRCSM #ASCO25
@ascocancer.bsky.social www.onclive.com/view/nivolum...
#ColorectalCancer #CRCSM #ASCO25
@ascocancer.bsky.social www.onclive.com/view/nivolum...
Let me know if you are looking for G13D patients for trials 😊🙏 I have G13D driven mCRC.
May 7, 2025 at 9:18 AM
Let me know if you are looking for G13D patients for trials 😊🙏 I have G13D driven mCRC.
🎥 Cancer Questions Answered: Episode 2
MCRC PhD student Adesewa Adebisi explains why cancer is so difficult to treat.
She explains how cancer’s diversity and adaptability make it one of medicine’s greatest challenges.
ow.ly/j9bh50WYNB9
MCRC PhD student Adesewa Adebisi explains why cancer is so difficult to treat.
She explains how cancer’s diversity and adaptability make it one of medicine’s greatest challenges.
ow.ly/j9bh50WYNB9
September 25, 2025 at 9:43 AM
🎥 Cancer Questions Answered: Episode 2
MCRC PhD student Adesewa Adebisi explains why cancer is so difficult to treat.
She explains how cancer’s diversity and adaptability make it one of medicine’s greatest challenges.
ow.ly/j9bh50WYNB9
MCRC PhD student Adesewa Adebisi explains why cancer is so difficult to treat.
She explains how cancer’s diversity and adaptability make it one of medicine’s greatest challenges.
ow.ly/j9bh50WYNB9
TTO intermitente c/fluorouracilo, leucovorina e irinotecán +panitumumab luego de inducción en pac c/CA colorrectal MT salvaje RAS/BRAF irresecable, mejora supervivencia libre de progresión en TTO c/menos toxicidad #FOLFIRI #panitumumab #mCRC ascopubs.org/doi/full/10....
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Cli...
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line
schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN)
prevents or delays the...
ascopubs.org
November 28, 2024 at 6:15 AM
TTO intermitente c/fluorouracilo, leucovorina e irinotecán +panitumumab luego de inducción en pac c/CA colorrectal MT salvaje RAS/BRAF irresecable, mejora supervivencia libre de progresión en TTO c/menos toxicidad #FOLFIRI #panitumumab #mCRC ascopubs.org/doi/full/10....
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer
https://buff.ly/3WpKTTy
TP demonstrated safe & effective chemo-free option for HER2-positive mCRC, w/ higher HER2 amplification predicting greater benefit
https://buff.ly/3WpKTTy
TP demonstrated safe & effective chemo-free option for HER2-positive mCRC, w/ higher HER2 amplification predicting greater benefit
January 22, 2025 at 1:20 PM
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer
https://buff.ly/3WpKTTy
TP demonstrated safe & effective chemo-free option for HER2-positive mCRC, w/ higher HER2 amplification predicting greater benefit
https://buff.ly/3WpKTTy
TP demonstrated safe & effective chemo-free option for HER2-positive mCRC, w/ higher HER2 amplification predicting greater benefit
🚨 New #OncologyPodcast Alert! 🚨
Join Profs @Tim Price & @JeanneTie to break down the latest expert consensus on #BRAFV600E-mutant #mCRC in the Asia-Pacific region
🎙️ PART 1: Molecular testing, treatment sequencing & BEACON insights—don’t miss it!
🔗 t.ly/idW9V #medsky #oncsky #cansky #GIsky #cancer
Join Profs @Tim Price & @JeanneTie to break down the latest expert consensus on #BRAFV600E-mutant #mCRC in the Asia-Pacific region
🎙️ PART 1: Molecular testing, treatment sequencing & BEACON insights—don’t miss it!
🔗 t.ly/idW9V #medsky #oncsky #cansky #GIsky #cancer
March 19, 2025 at 1:06 AM
🚨 New #OncologyPodcast Alert! 🚨
Join Profs @Tim Price & @JeanneTie to break down the latest expert consensus on #BRAFV600E-mutant #mCRC in the Asia-Pacific region
🎙️ PART 1: Molecular testing, treatment sequencing & BEACON insights—don’t miss it!
🔗 t.ly/idW9V #medsky #oncsky #cansky #GIsky #cancer
Join Profs @Tim Price & @JeanneTie to break down the latest expert consensus on #BRAFV600E-mutant #mCRC in the Asia-Pacific region
🎙️ PART 1: Molecular testing, treatment sequencing & BEACON insights—don’t miss it!
🔗 t.ly/idW9V #medsky #oncsky #cansky #GIsky #cancer
Not in Chicago but getting the updates - #ASCO25 learnings today:
😀there's an option in BRAFV600 mCRC
😀Ipi+Nivo better in MSI-h unresectable mCRC
🫤ctDNA+ still not guiding care in CC
😳CRS+HIPEC no better with chemo
@oncbrothers.bsky.social
got the details 👉🏻 tinyurl.com/bd75xjw7
#OncSky #MedSky
😀there's an option in BRAFV600 mCRC
😀Ipi+Nivo better in MSI-h unresectable mCRC
🫤ctDNA+ still not guiding care in CC
😳CRS+HIPEC no better with chemo
@oncbrothers.bsky.social
got the details 👉🏻 tinyurl.com/bd75xjw7
#OncSky #MedSky
tinyurl.com
May 31, 2025 at 1:47 AM
Not in Chicago but getting the updates - #ASCO25 learnings today:
😀there's an option in BRAFV600 mCRC
😀Ipi+Nivo better in MSI-h unresectable mCRC
🫤ctDNA+ still not guiding care in CC
😳CRS+HIPEC no better with chemo
@oncbrothers.bsky.social
got the details 👉🏻 tinyurl.com/bd75xjw7
#OncSky #MedSky
😀there's an option in BRAFV600 mCRC
😀Ipi+Nivo better in MSI-h unresectable mCRC
🫤ctDNA+ still not guiding care in CC
😳CRS+HIPEC no better with chemo
@oncbrothers.bsky.social
got the details 👉🏻 tinyurl.com/bd75xjw7
#OncSky #MedSky
#CRDF Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
https://www.stocktitan.net/news/CRDF/cardiff-oncology-announces-a-second-patent-for-the-treatment-of-m-plrr83hvyz2k.html
https://www.stocktitan.net/news/CRDF/cardiff-oncology-announces-a-second-patent-for-the-treatment-of-m-plrr83hvyz2k.html
Cardiff Oncology Wins Crucial Patent: Breakthrough Cancer Drug Now Covers All Bevacizumab-Naïve Patients
New patent extends protection for onvansertib cancer therapy to all bevacizumab-naïve mCRC patients through 2043. Phase 2 trial updates coming soon. Get Details.
www.stocktitan.net
April 23, 2025 at 8:05 PM
#CRDF Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
https://www.stocktitan.net/news/CRDF/cardiff-oncology-announces-a-second-patent-for-the-treatment-of-m-plrr83hvyz2k.html
https://www.stocktitan.net/news/CRDF/cardiff-oncology-announces-a-second-patent-for-the-treatment-of-m-plrr83hvyz2k.html
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers ..., ERK1/2 and STAT3 signaling ...
www.oncotarget.com/article/2860...
"Single-agent TAS102 (trifluridine/tipiracil) and regorafenib are FDA-approved treatments for metastatic colorectal cancer (mCRC)."
www.oncotarget.com/article/2860...
"Single-agent TAS102 (trifluridine/tipiracil) and regorafenib are FDA-approved treatments for metastatic colorectal cancer (mCRC)."
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and... | Oncotarget
https://doi.org/10.18632/oncotarget.28602 Jun Zhang, Lanlan Zhou, Shuai Zhao, Wafik S. El-Deiry
www.oncotarget.com
June 20, 2025 at 3:56 PM
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers ..., ERK1/2 and STAT3 signaling ...
www.oncotarget.com/article/2860...
"Single-agent TAS102 (trifluridine/tipiracil) and regorafenib are FDA-approved treatments for metastatic colorectal cancer (mCRC)."
www.oncotarget.com/article/2860...
"Single-agent TAS102 (trifluridine/tipiracil) and regorafenib are FDA-approved treatments for metastatic colorectal cancer (mCRC)."
There’s still time to sign up for our Taster Session on Thursday 30 October to learn more about studying a #PhD in Cancer Sciences.
⏰ Learn about our application process
🧑 Hear from current students
🐝 Learn what it’s like to study in Manchester
www.eventbrite.co.uk/e/cruk-mcrc-...
⏰ Learn about our application process
🧑 Hear from current students
🐝 Learn what it’s like to study in Manchester
www.eventbrite.co.uk/e/cruk-mcrc-...
CRUK MCRC PhD Taster Session 2025–2026 : Discover, Apply, Lead
From Curiosity to Cure: Explore PhD Opportunities at CRUK MCRC, Meet the Researchers and Map Your Future
www.eventbrite.co.uk
October 27, 2025 at 9:56 AM
There’s still time to sign up for our Taster Session on Thursday 30 October to learn more about studying a #PhD in Cancer Sciences.
⏰ Learn about our application process
🧑 Hear from current students
🐝 Learn what it’s like to study in Manchester
www.eventbrite.co.uk/e/cruk-mcrc-...
⏰ Learn about our application process
🧑 Hear from current students
🐝 Learn what it’s like to study in Manchester
www.eventbrite.co.uk/e/cruk-mcrc-...
